On this page
Almost every common GLP-1 side effect comes from one mechanism: these medicines slow how fast food leaves your stomach. Nausea, early fullness, reflux, constipation, and burping all follow from that single fact.
Most side effects are front-loaded. They’re worst in the weeks after each dose increase and ease as your body adapts, and only a short list of rare problems needs a clinician the same day.
That’s our whole clinical position. The rest of this page is the map: what happens, how often, and why, what goes away on its own, and where the red lines are. When a symptom needs its own guide, we link to it.
It’s mostly one mechanism
Semaglutide and tirzepatide mimic GLP-1, a hormone your gut releases after meals. Three effects are well established. They slow gastric emptying (how fast your stomach empties), quiet the appetite signals in your brain, and help your body release insulin, but only when your blood sugar is high. Tirzepatide also mimics a second gut hormone, called GIP. (The details on the drug itself are at semaglutide.)
The slow stomach explains most of the list. Food that sits longer pushes upward, which causes nausea, reflux, and burping. It also moves through more slowly, which causes constipation, and it fills you up sooner, sometimes before you’ve eaten your protein. Eating far less has effects of its own, too: fatigue, and sometimes lightheadedness.
The common cluster
STEP 1 (Wilding et al., NEJM 2021) studied 1,961 adults on brand-name semaglutide (Wegovy), who lost 14.9% of their body weight on average by week 68. SURMOUNT-1 (Jastreboff et al., NEJM 2022) studied 2,539 adults on brand-name tirzepatide (Zepbound), who lost up to 20.9% by week 72. Those papers are where the benefit numbers come from.
The same papers also report the side effects, and both show the same pattern. Gastrointestinal complaints topped the side effect tables, and most were mild to moderate. They bunched up during dose increases instead of lasting through the whole trial.
Here they are, roughly from most to least common:
- Nausea. The most common side effect of these drugs. It tends to be worse in the days after a shot and in the first weeks after a dose increase, then fades. The tips that help (timing, what to eat first, what to skip) are in GLP-1 nausea hacks.
- Early fullness. Mostly, this is the drug doing its job. It becomes a side effect when you can’t eat enough to hit your protein target, which we cover two sections down.
- Constipation. Food moves slower, you eat less, and you usually drink less water too. Of this whole group, it’s the one most likely to outlast your dose increases if you don’t deal with it. The plan is at GLP-1 constipation.
- Heartburn and reflux. A stomach that stays full longer puts more pressure on the valve at the top. GLP-1 heartburn and reflux covers what helps, and when reflux is a sign your dose got ahead of your gut.
- Burping, including sulfur burps. The leading explanation is that food ferments during its longer stay in your stomach. It’s unpleasant but harmless, and it usually improves with the same steps that help nausea and reflux.
- Diarrhea. It’s common and real, and it’s also the hardest one to explain. These hormones change how your gut moves in more ways than emptying, and we understand this one less well. It often alternates with constipation in the same person.
- Fatigue. You’re suddenly eating much less than your body is used to, so expect it in the first weeks. Tell your clinician if it lasts after your dose has been steady for a month.
- Injection-site reactions. Redness or a small itchy welt that’s mild and stays in one spot. Rotate between your belly, thigh, and the back of your upper arm.
- Hair shedding. A few months in, some people shed more hair than usual. It’s called telogen effluvium, and it happens because hair follicles react to rapid weight loss itself, the same pattern seen after bariatric surgery. It usually resolves on its own.
One more effect almost nobody files as a complaint: many people simply want alcohol less. The evidence is thin, coming from small trials and secondary analyses with no large randomized trial yet, so call it likely but unproven. Two practical notes either way. Alcohol on a slowed stomach hits harder than you’d expect, and its calories compete directly with your protein target.
The titration ladder is the treatment
On the Wegovy label, semaglutide goes up in steps of 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, moving about every 4 weeks. On the Zepbound label, tirzepatide starts at 2.5 mg and goes up by 2.5 mg every 4 weeks toward a maintenance dose of 5, 10, or 15 mg. Both the Wegovy and Zepbound labels say the same thing about this titration schedule: slow down if side effects call for it.
That instruction is the side effect plan. Each dose increase starts a short adjustment window, and each pause lets your gut catch up. Staying at 0.5 mg for an extra month is the label working as designed, and it has nothing to do with willpower. For many people, the stomach problems above ease as titration paces the drug’s effects. If they don’t, your clinician looks at how severe they are and decides whether to hold the dose or rethink the treatment.
The two drugs may differ in one way. Tirzepatide’s added GIP activity may make nausea milder at its higher doses, but no head-to-head trial has settled this, so don’t count on it.
The side effect you can’t feel
Part of the weight you lose on a GLP-1 is muscle. DXA body-composition scans in the STEP and SURMOUNT trials of brand-name semaglutide (Wegovy) and brand-name tirzepatide (Zepbound) measured it, and people lost lean mass as well as fat. Does that matter for strength, daily function, or fracture risk ten years from now? No one has studied it. We don’t know.
What we do know is the countermeasure, and it’s simple: strength training twice a week, and enough protein. A range often cited is about 1.2–1.6 g per kilogram of body weight per day, and your clinician can set your own target. Early fullness makes the protein the hard part, which is why it appears on the side effect list above instead of in a footnote.
Gallstones: partly the drug, mostly the speed
Rapid weight loss raises your gallstone risk however you achieve it, and strict diets and bariatric surgery do it too, because bile chemistry shifts when your body burns fat quickly. The GLP-1 trials recorded more gallbladder events than placebo did. GLP-1 and your gallbladder covers who is really at risk, what an attack feels like, and when a scan makes sense.
For this map, one thing matters most. Pain under your right ribs, especially after a fatty meal, is not routine nausea, so treat it as a same-day call.
The same-day list
Everything above is discomfort. This section is about danger. Contact your clinician the same day, or go to urgent care, for:
- Severe upper-belly pain that won’t go away. It may go through to your back, with or without vomiting. Treat it as pancreatitis (an inflamed pancreas) until a doctor rules it out. (A history of pancreatitis is also a reason for caution before starting at all, and it’s on both labels.)
- Pain under your right ribs with fever, or yellow skin or eyes. That points to your gallbladder, as described above.
- Repeated vomiting, or you can’t keep fluids down. Ongoing vomiting on a drug that also dulls your thirst is how dehydration can quietly turn into a kidney problem.
- A neck lump, new hoarseness, or trouble swallowing. It’s almost always something harmless, but these are exactly the symptoms the thyroid warning asks you to report.
- Swelling of the face or throat, or trouble breathing. Don’t message your clinician. Call 911.
One planned-care note surprises people. Anesthesia societies now advise telling your surgery or endoscopy team that you take a GLP-1 before any sedation, because your stomach may not be empty even after the usual overnight fast.
Zappy clinicians review every case within 24 hours, and messages about your dose don’t have to wait for a scheduled visit. The list above is what “don’t wait for your check-in” means.
The boxed warning, plainly
Both drugs caused thyroid C-cell tumors in rodents. Whether that risk carries over to humans is unknown: it hasn’t been shown in people, and it hasn’t been ruled out. So there’s a firm rule. Don’t take these drugs if you or anyone in your family has had medullary thyroid carcinoma or MEN 2. There’s a second firm rule, too: they are not for use in pregnancy. If you’re pregnant or planning to be, that changes the plan, so tell your clinician.
How long is the safety record, really?
It’s longer than skeptics assume, but it isn’t forever. The weight-loss trials lasted 68–72 weeks. The longer data comes from SELECT (Lincoff et al., NEJM 2023), which followed 17,604 adults with established cardiovascular disease on brand-name semaglutide (Wegovy) 2.4 mg for more than three years on average. That’s the largest long-term dataset for this class of drug, and its main result favored the drug: major heart events went down 20% in relative terms (HR 0.80). Watching 17,604 people for three-plus years is a real safety record. It is not a ten-year record.
Starting with your history in hand
The map above is general, but your risk is personal. Your thyroid history, any past pancreatitis, plans for pregnancy, and what your gut already does in a normal week all matter. Those are the questions the five-minute intake asks, because they turn this general map into one that fits you.
What we still don’t know
Two open questions matter most. The first is duration. SELECT takes the safety record to about three years, and these drugs are meant for long-term use, but ten-year data doesn’t exist because ten years haven’t passed yet.
The second is body composition. DXA scans tell us part of the weight lost is lean mass, but no trial has tested whether that changes strength, fracture risk, or independence at 70. None has tested whether two strength sessions a week fully close the gap, either. That second answer is the one to watch for.
